Heparin-binding protein is important for vascular leak in sepsis by unknown
RESEARCH Open Access
Heparin-binding protein is important for
vascular leak in sepsis
Peter Bentzer1,2,4, Jane Fisher3,4, HyeJin Julia Kong4, Mattias Mörgelin3, John H. Boyd4, Keith R. Walley4,
James A. Russell4 and Adam Linder3,4*
* Correspondence:
adam.linder@med.lu.se
3Department of Infectious Diseases,
University of Lund and Skåne
University Hospital, Getingevägen,
Lund SE-221 85, Sweden
4Centre for Heart Lung Innovation,
Division of Critical Care Medicine,
St. Paul’s Hospital, University of
British Columbia, Vancouver, BC,
Canada
Full list of author information is
available at the end of the article
Abstract
Background: Elevated plasma levels of heparin-binding protein (HBP) are associated
with risk of organ dysfunction and mortality in sepsis, but little is known about
causality and mechanisms of action of HBP. The objective of the present study was
to test the hypothesis that HBP is a key mediator of the increased endothelial
permeability observed in sepsis and to test potential treatments that inhibit HBP-
induced increases in permeability.
Methods: Association between HBP at admission with clinical signs of increased
permeability was investigated in 341 patients with septic shock. Mechanisms of
action and potential treatment strategies were investigated in cultured human
endothelial cells and in mice.
Results: Following adjustment for comorbidities and Acute Physiology and Chronic
Health Evaluation (APACHE) II, plasma HBP concentrations were weakly associated
with fluid overload during the first 4 days of septic shock and the degree of
hypoxemia (PaO2/FiO2) as measures of increased systemic and lung permeability,
respectively. In mice, intravenous injection of recombinant human HBP induced a
lung injury similar to that observed after lipopolysaccharide injection. HBP increased
permeability of vascular endothelial cell monolayers in vitro, and enzymatic removal
of luminal cell surface glycosaminoglycans (GAGs) using heparinase III and
chondroitinase ABC abolished this effect. Similarly, unfractionated heparins and low
molecular weight heparins counteracted permeability increased by HBP in vitro.
Intracellular, selective inhibition of protein kinase C (PKC) and Rho-kinase pathways
reversed HBP-mediated permeability effects.
Conclusions: HBP is a potential mediator of sepsis-induced acute lung injury
through enhanced endothelial permeability. HBP increases permeability through an
interaction with luminal GAGs and activation of the PKC and Rho-kinase pathways.
Heparins are potential inhibitors of HBP-induced increases in permeability.
Keywords: Septic shock, Heparin-binding protein (HBP), Vascular leak, Acute
respiratory distress syndrome, Permeability
Background
A key feature in the pathophysiology of adult respiratory distress syndrome (ARDS)
and septic shock is increased microvascular permeability; however, the current under-
standing of the underlying mechanisms is limited [1]. Furthermore, no therapy directly
targeting increased microvascular permeability is currently available in sepsis.
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Heparin-binding protein (HBP), also known as azurocidin or CAP37, is stored in
secretory vesicles and azurophilic granules of neutrophils and is released early upon
neutrophil adhesion and during neutrophil extravasation. Bacterial products induce re-
lease of HBP leading to increased vascular leakage by acting on endothelial cells
through largely unknown mechanisms [2]. It has been shown that HBP binds to cell
surface proteoglycans, but the importance of this binding for permeability increases has
not been investigated [3, 4]. Moreover, the importance of HBP on the pathophysiology
and outcomes of sepsis is unclear. Support for the importance of the permeability-
increasing effect of HBP may be inferred from the observation that elevated plasma
levels of HBP are associated with shock in septic patients [5–7]. Furthermore, while
patients with severe ARDS have been shown to have higher HBP levels than those with
less severe ARDS [8], it is unclear if increased levels of HBP merely reflect injury sever-
ity or if there is a causal relationship between HBP and ARDS.
Based on these considerations, the first objective of the present study was to test the
hypothesis that elevated levels of HBP are associated with severity of fluid overload and
ARDS—as indirect markers of increased permeability in a cohort of patients with septic
shock. Based on findings compatible with a role for HBP in vascular leakage in septic
shock, our second objective was to use in vitro and in vivo models to investigate the
cellular mechanisms involved in the permeability-increasing effect of HBP and, finally,




Plasma concentrations of HBP were analyzed in a subgroup of patients included in the
Vasopressin and Septic Shock Trial (VASST) cohort of septic shock patients [9]. VASST
was a multicenter randomized double-blind controlled trial in which adult patients with
septic shock requiring vasopressor support (at least 5 μg/min of noradrenaline) for at
least 6 h despite adequate fluid resuscitation were eligible for inclusion (n = 778). Pa-
tients were randomized to receive either masked vasopressin or noradrenaline to reach
a target mean arterial pressure of 65 to 75 mmHg until shock had resolved. Infusion of
the study drug was started 12 ± 9 h after meeting inclusion criteria and plasma that was
collected at baseline (within 2 h of start of infusion of the study drug) was available for
341 patients. The research ethics boards of all 27 participating centers approved the
VASST (Current Controlled Trials number, ISRCTN94845869). Written informed
consent was obtained from patients, next of kin, or surrogate decision-makers as ap-
propriate. Plasma concentration of HBP was measured in duplicate blinded to clinical
outcomes using a commercial HBP ELISA (Axis-Shield Diagnostics Ltd.). Plasma
concentration of IL-6 was measured in duplicate using a Luminex multiplex bead assay
(Luminex, Austin, TX).
Outcome measures
The primary outcome was the relationship between HBP concentration in plasma and
percent fluid overload. Percent fluid overload is a marker of increased vascular leakage
and was calculated at 6, 12, 24, and 48 h after inclusion using the following formula:
(fluid intake − fluid output)/(body weight (kg))*100 [10, 11]. The secondary outcome
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was the association between plasma HBP concentration at baseline and lung permeabil-
ity. Because radiologic data and ventilator settings were unavailable, PaO2/FiO2 was
used as a surrogate marker of increased lung permeability and ARDS. In addition, we
examined the association between plasma HBP concentration at baseline and severity
of shock measured as norepinephrine dose and plasma lactate concentration during the
first 5 days after admission.
In vitro studies
Human endothelial cell model
Immortalized human umbilical vein endothelial cells (EA.hy926, American Type
Culture Collection) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % fetal bovine serum (FBS) (both from Life Technologies). For
all permeability measurements, cells were cultured to confluence (3 days) on ThinCert
transparent inserts with a 3-μm pore size (Greiner Bio-One). Experiments with these
cells were carried out in serum-free DMEM. Human recombinant HBP was used for all
in vitro experiments (R&D Systems) and in vivo experiments (Novoprotein).
Permeability assays
Trans-endothelial electrical resistance (TEER) reflects paracellular small molecule perme-
ability, and a decrease in TEER reflects an increased permeability. TEER was measured
using an EVOM system with STX2 electrodes (World Precision Instruments) as described
previously [12]. Confluence of the monolayer was confirmed by microscopic inspection
and by measuring a resistance across the monolayer of at least 50 Ω more than that of a
well with no cells. To validate that changes in TEER reflected physiologically important
permeability changes, macromolecule permeability was determined by measuring diffu-
sion of streptavidin-conjugated horseradish peroxidase (HRP) (MW ≈ 100 kDa) in some
of the experiments as described in detail in Additional file 1.
Glycosaminoglycan digestion
Cells cultured on permeable inserts were treated with 15 mU/mL of Heparinase III
(New England Biolabs) or 2.5 mU/mL Chondroitinase ABC (R&D Systems) for 1 h at
37 °C [13]. Cells were then stimulated with HBP and TEER, and HRP passage was mea-
sured after 1.5 h.
Evaluation of HBP signaling pathways
For inhibition of signaling pathways, cells were pretreated for 1 h at 37 °C with Y-27
632 (Tocris) at a concentration of 1 μM [14] or Calphostin C (Tocris) at a dose of
50 nM [15] to inhibit Rho-kinase and protein kinase C (PKC), respectively.
Effects of heparin compounds on HBP-induced increased permeability
The putative inhibitors of HBP were unfractionated heparin (UFH) (Leo) and three low
molecular weight heparins (LMWHs): dalteparin (Pfizer), enoxaparin (Sanofi-Aventis),
and tinzaparin (Leo). Varying doses of UFH were tested to determine the minimally
effective dose. Therapeutic plasma levels of heparin in humans are 0.3–0.7 U/mL, and
a concentration range of 0.01–100 U/mL was examined [16]. The LMWHs were dosed
to obtain the clinical therapeutic level of 1 anti-Xa IE/mL [17]. HBP (10 μg/mL) was
mixed with the various heparins, incubated at 37 °C for 20 min, and cells were subse-
quently stimulated with this mixture.
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In vivo studies
Lund University Ethical Committee for Animal Research approved the experimental
protocol. Adult male C57BL/6 mice (Taconic) weighing 26 ± 2 g were used. Mice were
treated in accordance with the National Institutes of Health for the Care and Use for
Laboratory Animals. After induction of anesthesia and preparation, as described in
detail in Additional file 1, animals received one of three treatments: (1) HBP 100 μg
intravenously followed by an infusion of 2.5 μg/g/h for 1 h (n = 3), (2) UFH at a dose of
0.4 U/g followed by HBP 100 μg intravenously followed by infusion of HBP as de-
scribed above (n = 3). This dose has previously been shown to double activated partial
thromboplastin time in mice and is therefore in the therapeutic range [18]. (3) Control:
bolus dose of 100 μL of vehicle (10 mM phosphate-buffered saline (PBS)) followed by
infusion of vehicle at 1.25 μL/g/h (n = 3).
At 1 h after start of treatment, animals were killed by exsanguination and the lungs
were collected for electron microscopy and histologic analysis as described in
Additional file 1. An investigator blinded to the treatment status of the animals per-
formed preparation and analysis of electron microscopic and histologic images as de-
scribed in detail previously [19]. Briefly, histologic analysis was done by scoring three
lung sections from each animal for alveolar thickness, capillary congestion, and cellular-
ity using a score from 0 to 3 with 3 being the highest injury score. An overall score was
calculated by averaging the three indices of injury. The shed blood was collected for
measurement of plasma concentrations of HBP as described above. Electron micros-
copy and histology preparations were compared to those obtained from mice sacrificed
at 4 h after intraperitoneal injection of lipopolysaccharide (LPS) from Escherichia coli
0111:B4 (Sigma-Aldrich) in a dose of 0.25 mg [20] after preparation as described above.
Statistical analysis
Comparisons between groups were made using the non-parametric Mann-Whitney test,
Student’s t test, one-way ANOVA, and two-way repeated measures ANOVA as appropriate.
Spearman’s non-parametric correlation coefficient (rho) was used to assess correlations be-
tween HBP levels and percent fluid overload and PaO2/FiO2. Two-tailed P values of less
than 0.05 were considered to be significant. Adjusted analyses were done by a logistic re-
gression model for presence of severe ARDS (PaO2/FiO2 ≤100 mmHg [≤13.3 kPa]) and
adjusting for age, gender, Acute Physiology and Chronic Health Evaluation (APACHE) II,
comorbidities, and physiological parameters and laboratory variables that differed signifi-
cantly between the patients with PaO2/FiO2 ≤100 or >100 mmHg, respectively (Table 1).
Data are expressed as mean ± standard deviation unless stated otherwise. Data were ana-
lyzed using GraphPad Prism (version 6.0, GraphPad Software, Inc.) and SPSS (version 19.0).
Results
Plasma HBP is associated with fluid overload
Median plasma concentration of HBP at baseline for the whole cohort was 25 ng/mL
(range, 0–361, interquartile range (IQR) 8–71). For comparison, median HBP levels are
reported to be 6 (range, 2–9 ng/mL) in healthy controls using a similar methodology
[21]. We tested the hypothesis that increased vascular leakage, as reflected by percent
fluid overload, was correlated with HBP concentration. Increased plasma HBP was very
weakly correlated with percent fluid overload at 6 h (rho 0.13, P = 0.01, Fig. 1a).
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HBP is associated with severity of hypoxemia
Increased plasma concentration of HBP correlated weakly with the lowest PaO2/FiO2 at
any time in the first 5 days after admission, as an indicator of severity of ARDS (rho
−0.25, P < 0.001, Fig. 1b). Patients with severe hypoxemia as defined by a PaO2/FiO2
≤100 mmHg at any time in the first 5 days after admission were hemodynamically more
compromised at baseline and had higher APACHE scores than patients with PaO2/
FiO2 >100 mmHg (Table 1). Plasma HBP concentration was 47 (IQR 23–123) and 22
(IQR 7–62) in the groups with PaO2/FiO2 ≤100 mmHg and PaO2/FiO2 >100 mmHg,
respectively (P < 0.01). Logistic regression adjusting for ethnicity, gender, age, APACHE
II, site of infection, chronic heart failure, COPD, chronic steroid treatment, chronic dia-
lysis and chronic hepatic failure, lactate concentration, norepinephrine dose and IL-6
concentrations showed that plasma HBP concentrations remained associated with pres-
ence of severe hypoxemia as defined above (P = 0.003). Plasma HBP was also positively
correlated with severity of shock as indicated by dosage of noradrenaline and plasma
lactate concentrations at days 1–4 (see Additional file 2: Figure S1 for day 1 data).








Male, n (%) 201 (59) 163 (57) 37 (70) 0.13
Age, years (median (IQR)) 63 (50.6–72.4) 63 (50.6–72.2) 64 (49.8–73.6) 0.93
Caucasian, n (%) 307 (90) 261 (92) 42 (79) <0.01
APACHE II (median (IQR)) 26 (21–32) 26 (21–32) 29 (24–35) <0.01
Comorbidities, n (%)
Chronic heart failure 26 (8) 21 (7.4) 5 (9.4) 0.82
COPD 58 (17) 53 (19) 5 (9.4) 0.15
Chronic steroids 72 (21) 60 (21) 11 (21) 1.0
Chronic dialysis 30 (9) 23 (8.1) 6 (11) 0.62
Chronic hepatic failure 37 (11) 29 (10) 8 (15) 0.43
Infection site, n (%)
Lung 147 (43) 112 (40) 34 (64) <0.01
Abdomen 89 (26) 80 (28) 8 (15) 0.07
Other 105 (31) 91 (32) 11 (21) 0.14
Physiological and laboratory variables at baseline, median (IQR)
MAP (mmHg) 56 (50–62) 56 (50–62) 55 (48–61) 0.22
Lactate (mmol/L) 1.7 (0.9–3.4) 1.6 (0.8–3.2) 2.5 (1.3–5.0) <0.01
Norepinephrine (μg/min) 13 (8–25) 12 (8–22) 23 (11–38) <0.01
WBC (109 cells/L) 14 (8–21) 14 (8–21) 11 (7–19) 0.18
Platelets 172 (90–259) 174 (90–268) 153 (108–238) 0.25
Temperature (°C) 38.6 (37.7–39.3) 38.5 (37.7–39.3) 38.7 (37.8–39.2) 0.49
PaO2/FiO2 192 (142–260) 205.3 (162–271) 99 (82.5–110.8) <0.01
IL-6 (pM) 4.3 (1.5–37) 5.6 (1.5–24) 18.9 (2.1–422) <0.01
Outcomes other than mortality, median (IQR)
DAF ventilator support 9 (0–21) 13 (1–22) 0 (0–2) <0.01
DAF renal replacement therapy 27 (7–28) 28 (12–28) 4 (1–16) <0.01
Groups were compared using the Student’s t test, or Mann-Whitney test, or chi-squared test as appropriate
DAF days alive and free, WBC white blood cell count, PaO2 arterial partial pressure of oxygen, FiO2 fraction of
inspired oxygen
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HBP increases in vitro permeability
Having established that elevated HBP is associated with physiological findings in keep-
ing with enhanced vascular permeability in septic patients, we went on to further inves-
tigate HBP’s mechanisms of action in human endothelial cells. To confirm previous
results demonstrating a permeability-increasing effect of HBP on endothelial cell
monolayers [2], effects of HBP upon the permeability of endothelial cell monolayers
were measured 1.5 h following HBP stimulation. Cell monolayers stimulated with HBP
had lower TEER and higher HRP passage than controls indicating that HBP induced
increased human endothelial cell permeability (Fig. 2a, b). Cell monolayers stimulated
with HBP reached a minimum TEER by 30 min to 1 h following stimulation (Fig. 2a).
Similarly, monolayers stimulated with HBP had a higher HRP passage at the earliest
Fig. 1 Elevated plasma HBP levels are associated with markers of increased vascular leakage. a Scatterplot of
plasma HBP levels at baseline and percent fluid overload at 6 h after admission. Dotted lines mark median value
for HBP and percent fluid overload, respectively. b Scatterplot of plasma HBP levels at baseline and lowest
PaO2/FiO2 during the first 5 days after admission. Dotted lines mark median value for HBP and PaO2/FiO2 fluid
overload, respectively. Spearman’s non-parametric correlation coefficient (rho) is given in the figures
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time points measured at 1 h, after which HRP diffusion reached equilibrium in all con-
ditions (Fig. 2b).
HBP acts by binding endothelial proteoglycans
In order test our hypothesis that binding of HBP to endothelial proteoglycans is re-
quired for the increased permeability, Heparinase III or Chondroitinase ABC were used
to selectively cleave either heparan sulfate or chondroitin sulfate/dermatan sulfate, re-
spectively, from the endothelial surface [3, 22–24]. Pre-treatment with Heparinase III
and Chondroitinase ABC did not affect basal permeability but attenuated HBP-induced
increase in permeability suggesting a role for proteoglycans as receptors in HBP-
induced vascular endothelial permeability increase (Fig. 3).
HBP increases permeability through PKC and the Rho-kinase pathways
Because activation of the PKC pathway may increase endothelial permeability [25] and
because HBP is shown to stimulate PKC activity [26], we tested the hypothesis that
Fig. 2 HBP increases the permeability of human endothelial cell monolayers. a EA.hy926 cells were grown to
confluence on permeable supports and stimulated with HBP. TEER across the filter was monitored over time.
The overall difference was determined by two-way ANOVA (treatment effect P = 0.001, time effect P < 0.001).
b HRP was added to the top chamber, and HRP passage was monitored over time. Values are normalized to
the TEER of empty inserts. The overall difference was determined by two-way repeated measures ANOVA
(treatment effect P = 0.009, time effect P < 0.001). In both experiments, Sidak’s multiple comparison post hoc
test was used to compare HBP treatment and control at each time point. Error bars are standard error of the
mean, n = 3. Some error bars are not visible due to scale. *P < 0.05, **P < 0.01, ***P < 0.001
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HBP increases permeability via the PKC pathway. HBP-induced permeability increase
could be blocked by the unselective PKC inhibitor Calphostin C. Activation of PKC is
reported to increase permeability of endothelial cells via the Rho-kinase pathway [27].
The Rho-kinase inhibitor Y-27 632 also attenuated HBP-induced increases in perme-
ability (Fig. 4).
HBP alone induced acute lung injury in vivo
While HBP is associated with findings suggestive of increased vascular permeability in
human septic shock, this association does not prove causality because many other
mediators contribute to human septic ARDS. Therefore, we used a murine model to
test the hypothesis that HBP causes acute lung injury (ALI) in vivo. HBP administration
induced histologic features characteristic of ALI including increased cellularity and
overall lung injury score compared to vehicle-treated control animals (Table 2 and
Fig. 5). Electron microscopy showed protein deposits and almost complete disappear-
ance of alveoli. HBP induced histological and electron microscopic changes very similar
Fig. 3 Effects of enzymatic removal of heparan sulfate or chondroitin sulfate by Heparinase III and Chondroitinase
ABC on HBP-induced permeability increases. EA.hy926 cells were grown to confluence on permeable supports
and treated with heparinase III (Hep. III) or Chondroitinase ABC (Chondro. ABC) for 1 h and then stimulated with
HBP. a TEER was measured after 1.5 h after HBP stimulation. b HRP was also added to the top chamber, and HRP
passage was measured 2 h after HBP stimulation. TEER values are normalized to the TEER of empty inserts.
Error bars are standard error of the mean, n = 3 for each condition. In both experiments, one-way ANOVA
with Dunnett’s test for multiple comparisons was used to compare each group to the condition with HBP
and no enzyme treatment (far right). *P < 0.05, **P < 0.01, ***P < 0.001
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to those observed after LPS administration (Fig. 5). Plasma concentration of HBP at the
end of the experiment was 400 ± 157 ng/mL in HBP-treated animals and 1.1 ± 1.5 ng/mL
in control animals.
The effect of HBP is inhibited by heparins
Based on the observation that heparins are known to bind to HBP [28], we hypothesized
that heparins could prevent the permeability-increasing effects of HBP. Heparin pre-
vented HBP-induced increased permeability: there was dose-dependent inhibition of al-
tered TEER and HRP permeability following co-stimulation of human endothelial cells
with HBP and unfractionated heparin (UFH) (Fig. 6). Maximum inhibition of permeability
increases by HBP was seen at concentrations of UFH in the range of 0.1–1 U/mL. Low
molecular weight heparins in the therapeutic range also inhibited the TEER-increasing ef-
fect of HBP (Fig. 7). In another set of experiments, UFH was added to cells after 1 h of
stimulation with HBP. TEER increased to 89 ± 1.0 % of baseline 1 h after UFH was added
whereas HBP-treated cells to which no UFH was added remained at 77 ± 4.0 % of baseline
(P < 0.01, Fig. 8). Treatment with UFH prior to administration of HBP in vivo appeared to
prevent both histological and electron microscopic appearance, but no significant change
in histologic score could be detected (Fig. 5 and Table 2).
Fig. 4 Effect of inhibition of signaling pathways in HBP-induced permeability increases. EA.hy926 cells were
grown to confluence on permeable supports and treated with Y-27 632 (Rho-kinase inhibitor) and Calphostin
C (PKC inhibitor) for 1 h and then stimulated with HBP. TEER across the filter was measured 1.5 h after HBP
stimulation and is normalized to empty inserts. Error bars are standard error of the mean, n = 3 for each
condition. One-way ANOVA with Dunnett’s test for multiple comparisons was used to compare each group
to the condition with HBP and no inhibitor (far right). *P < 0.05, **P < 0.01, ***P < 0.001
Table 2 Lung histologic injury score
Alveolar thickness Capillary congestion Cellularity Overall score
Vehicle (n = 3) 0.33 ± 0.88 0.5 ± 0.05 0.67 ± 0.29 0.5 ± 0.33
HBP (n = 3) 1.89 ± 0.84 1.78 ± 0.69 2.06 ± 0.59* 1.91 ± 0.7*
HBP + UFH (n = 3) 0.67 ± 1.15 2.67 ± 0.58 0.33 ± 0.58# 1.22 ± 0.69
LPS (n = 3) 2.5 ± 0.71* 2.25 ± 0.35* 2.00 ± 0.0* 2.25 ± 0.35*
One-way ANOVA. The Sidak method was used to correct for multiple comparisons
UFH unfractionated heparin, LPS lipopolysaccharide
*P < 0.05 compared to vehicle, #P < 0.05 compared to HBP
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Discussion
Our results show that increased plasma HBP concentration in human septic shock is
associated with increased vascular leak as reflected indirectly by percent fluid overload
and the severity of hypoxemia. In addition, HBP increased permeability in vitro. Fur-
thermore, administration of HBP in a murine model rapidly induces a lung injury simi-
lar to that observed after LPS administration. The presence of heparan sulfate and
chondroitin sulfate moieties on the endothelial cell surface is required for HBP-induced
increased permeability as shown by enzymatic degradation of these compounds, which
Fig. 5 HBP-induced signs of acute lung injury in mice in vivo. Mice were injected with intravenous heparin-
binding protein (HBP) and/or unfractionated heparin (UFH) followed by continuous infusion for 1 h. Controls
received vehicle (10 mM phosphate-buffered saline). The lungs were stained with hematoxylin and eosin (left)
or analyzed by scanning electron microscopy (right). Hematoxylin and eosin-stained sections were scored for
alveolar thickness, capillary congestion, and cellularity (see Table 2). Images from sections with a median overall
score are shown. Histologic and electron microscopic images of mice treated with intraperitoneal lipopolysaccharide
(LPS) from Escherichia coli 0111:B4 in a dose of 0.25 mg for 4 h are presented in lower panels
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completely abolished the permeability-increasing effect of HBP. Downstream signaling
occurs via the protein kinase C and Rho-kinase pathways as shown by experiments
using selective inhibitors. The permeability increase by HBP in human endothelial cells
was inhibited by pre-treatment and post-treatment with UFH and low molecular weight
heparins.
To the best of our knowledge, this is the first report showing that increased plasma
HBP levels are associated with the presence or development of severe hypoxemia in a
cohort of patients suffering from septic shock. These results are in line with a study
showing that increased plasma HBP at admission in trauma patients is correlated with
development of ARDS [29]. The results also align with the association between hypox-
emia and plasma levels of HBP in a small cohort of patients with influenza infection
[30]. However, our results are in contrast with a recent study in which there was no
correlation between HBP and development of hypoxemia in patients with severe sepsis
[31]. Given the small number of septic patients in that study (n = 83), it could be hy-
pothesized that difference in results could be related to a possible false negative due to
lower power in the study by Tydén et al. compared to the higher sample size (n = 341)
and statistical power of our study. The finding that HBP concentrations at baseline in
VASST are correlated with indirect markers of increased systemic vascular leakage
Fig. 6 Unfractionated heparin blocked HBP-induced permeability increases. EA.hy926 cells were grown to
confluence on permeable supports and stimulated with 10 μg/mL HBP, pre-incubated with the indicated
dose of heparin. a TEER was measured 1.5 h after stimulation and is normalized to empty inserts. b HRP
was also added to the top chamber, and HRP passage was measured 2 h after stimulation. Error bars are standard
error of the mean, n= 3 for each condition. One-way ANOVA with Dunnett’s test for multiple comparisons was
used to compare each group to the condition with HBP and no heparin (far left).*P< 0.05, **P< 0.01, ***P< 0.001
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during the first days of septic shock corroborates previous results suggesting that in-
creased plasma HBP levels at hospital admission predict shock [5–7]. Taken together,
these results indicate that plasma levels of HBP may be used to identify patients at risk
for development of ARDS and increased systemic vascular leakage and indicate that
HBP may be a clinically important mediator of permeability increase in septic shock.
The finding that the associations between HBP and markers suggestive of increased per-
meability were weak could reflect the complex pathophysiology of sepsis with multiple re-
dundant pathways leading to increased permeability [1]. Moreover, indirect markers of
increased permeability are likely to be influenced by factors, which are unrelated to
changes in permeability. The timing of the plasma sampling may also falsely underesti-
mate the association between HBP and markers of permeability, as discussed below.
Fig. 7 Low molecular weight heparins blocked HBP-induced permeability increases. EA.hy926 cells were
grown to confluence on permeable supports and stimulated with 10 μg/mL HBP, pre-incubated with the
indicated inhibitor. TEER was measured after 1.5 h after stimulation and is normalized to empty inserts. Error
bars are standard error of the mean, n = 3 for each condition. One-way ANOVA with Dunnett’s test for
multiple comparisons was used to compare each group to the condition with HBP and no inhibitor (far left).
UFH unfractionated heparin. *P < 0.05, **P < 0.01
Fig. 8 Unfractionated heparin reversed HBP-induced permeability increases. EA.hy926 cells were grown to
confluence on permeable supports and stimulated with 10 μg/mL HBP. At 1 h following stimulation, HBP-
containing media were removed and replaced with fresh media (gray line, treatment 1), or heparin was
added to a final concentration of 3 U/mL (dashed line, treatment 2), or no change was made (black line,
treatment 3). TEER across the filter was monitored over time and is normalized to empty inserts. The overall
difference was determined by two-way repeated measures ANOVA (treatment effect P = 0.002, time effect
P < 0.001). Sidak’s multiple comparisons post hoc test was used to compare treatments 1 and 2 to treatment 3
at each time point. Error bars are standard error of the mean, n = 3 for each intervention. UFH unfractionated
heparin. **P < 0.01, ***P < 0.00
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Topical application of HBP has previously been show to induce rapid leakage of
FITC-labeled dextran in the hamster cheek pouch preparation [2]. However, to date,
the effects of intravenous HBP on a whole animal model have not been investigated.
Our finding that HBP rapidly induced histological changes consistent with acute lung
injury supports the hypothesis that HBP induces increased capillary leak in the lung in
vivo and supports a causal relationship between HBP and ARDS.
HBP binds to proteoglycans on endothelial cells, but the functional importance of
this binding for increases in permeability has not been investigated before [3, 4]. Pro-
teoglycans are membrane-bound molecules with a protein core to which polysaccha-
rides containing heparan sulfate (HS) and chondroitin sulfate (CS) chains are bound.
The syndecans [1–4] are composed of a transmembrane protein core to which HS
chains and sometimes CS chains are attached. The glypicans [1–6], with the exception
of glypican-5, carry only HS side chains [32, 33]. To date, the expression of all synde-
cans and glypican-1 and glypican-4 has been described on endothelial cells and
syndecan-4 is the predominant syndecan in cultured human endothelial cells [34, 35].
Our result showing that cleavage of both HS and of CS can inhibit the permeability-
increasing effect of HBP indicates that syndecans act as receptors for HBP [36]. Proteo-
glycans are known to act both as primary receptors and as co-receptors that facilitate
binding of agonists to other receptors, and thus, the involvement of other receptors for
HBP remains a possibility [32, 34].
Our screening of potential intracellular signaling pathways identified PKC as one of the
most likely pathways mediating the permeability-increasing effect of HBP on endothelial
cells. The result that inhibition of PKC inhibits the permeability-increasing effect of HBP
aligns with previous results showing that HBP increases intracellular calcium and activates
PKCα in endothelial cells [2, 26]. Interestingly, activation of syndecan-4 has been sug-
gested to influence stress fiber formation in fibroblasts through a calcium-independent
PKCα activation mechanism indicating that increased intracellular calcium may not be a
prerequisite for increases in permeability [37, 38]. At present, it is unclear if Rho-kinase
activation is downstream of PKC activation or if it represents a parallel pathway.
One small high-quality RCT has investigated the effect of heparin treatment on mor-
tality in sepsis and could not demonstrate a benefit of heparin treatment on mortality
or severity of ARDS [39]. However, several retrospective analyses and meta-analyses
have indicated that heparin treatment may reduce mortality in septic shock [40–42]
while one retrospective study could not demonstrate an effect of heparins on ARDS
[43]. Given the association between HBP and clinical signs consistent with vascular leak
and the permeability-increasing effect in vitro, HBP represents a potential target for
therapeutic intervention in sepsis. Our result that both UFH and low molecular weight
heparins inhibited permeability increases induced by HBP suggests a cogent rationale
for further studies of heparin(s) to prevent sepsis-induced ARDS and vascular leak. Fur-
thermore, our results raise the possibility that HBP levels in plasma may be used to
identify a subset of patients with septic shock that may benefit from treatment with
heparin in future trials. It should be noted that a recent meta-analysis suggested that
safety aspects of heparin in sepsis are underreported, and we conclude that risk of
bleeding is a potential concern for the application of heparin in this setting [41].
We acknowledge that this study has several limitations. Firstly, baseline blood sam-
ples in the VASST cohort were collected within 2 h of start of treatment with the study
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drug, which occurred about 12 ± 9 h after meeting inclusion criteria [9]. Given that
plasma HBP levels change rapidly [6], we cannot exclude that the variability in the tim-
ing of blood sampling could have influenced our results and potentially underestimated
the association between HBP and our indirect clinical markers of increased permeabil-
ity. Secondly, the high cost of recombinant HBP limited the number and length of in
vivo experiments that could be performed and prevented us from a more detailed
evaluation of physiological effects by HBP in vivo.
Conclusions
Taken together, our clinical and experimental data suggest a causal relationship be-
tween HBP, increased permeability, and ARDS in human sepsis. Unfractionated heparin
and low molecular weight heparins are potential drugs to prevent excessive HBP-
induced increases in vascular leak in sepsis.
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